Novogen Makes Changes to the Board with Appointment of New Chairman and Deputy Chairman

Novogen Limited (ASX:NRT;NASDAQ:NVGN), announced today the appointment of a new Chairman, Mr John O’Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately.
According to the company’s press release.

About John O’Connor
Mr John O’Connor, BEC, MAICD has more than 30 years’ experience in the financial industry and was appointed to the Novogen Board in May 2012. During his career, he has held numerous management roles as a fund manager and stockbroker in the UK, US andAustralia as well as a partnership in a securities business. He has been a consultant to several biotech companies, including Novogen Limited and Marshall Edwards Inc., and has assisted with fundraising.
Mr O’Connor served on the Board of Lonsec Securities, a Zurich Insurance-owned business for several years.
About Bryce Carmine
Mr Bryce Carmine has 36 years’ experience with one of the world’s largest pharmaceutical companies where he held numerous roles including Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines business unit. For much of that time, as a senior executive, he was responsible for Eli Lilly’s global late-stage drug development pipeline. Mr Carmine holds US residency and brings to the Board a strong understanding of the drug development process and dynamics of the pharmaceutical industry. He will continue to Chair the Board’s Scientific Committee.
Mr Carmine is currently Chairman and CEO of a Sydney-based biotechnology company, HaemaLogiX. He holds a B.Sc. in biochemistry from Massey University in New Zealand.

Click here to view the full press release.